RecruitingPhase 3NCT04020263

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

Studying Cardiogenic shock

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Pr Bruno LEVY
Principal Investigator: Clément DELMAS, Dr
University Hospital, Toulouse
Intervention: Levosimendan 2.5 MG/ML Injectable Solution(drug)
Enrollment: 610 enrolled
Eligibility: 18 years · All sexes
Timeline: 2023 – 2028

Study locations (28)

CHRU Strasbourg -Nouvel Hôpital Civil, Strasbourg, Bas-Rhin, France
AP-HM, Nord Hospital, Marseille, Marseille, Bouches du Rhône, France
CHU Caen, Caen, Calvados, France
CHU Dijon, Dijon, Côte d'Or, France
CHU Besançon Jean Minjoz Hospital, Besançon, Doubs, France
CHU Nîmes, Carémeau Hospital, Nîmes, Gard, France
CHU Bordeaux - Hopital haut-leveque, Bordeaux, Gironde, France
CHU de Toulouse, Toulouse, Haute-Garonne, France
CHU Limoges, Dupuytren Hospital, Limoges, Haute-Vienne, France
CHU Montpellier, Arnaud de Villeneuve Hospital, Montpellier, Hérault, France
CHU Rennes, Pontchaillou Hospital, Rennes, Ille et Vilaine, France
CHU Grenoble, Michallon Hospital, La Tronche, Isère, France
CHU Nantes, Nantes, Loire-Atlantique, France
CHR Metz-Thionville, Mercy Hospital, Ars-Laquenexy, Moselle, France
CHRU Lille, Cœur Poumon Institute, Lille, Nord, France
+13 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04020263 on ClinicalTrials.gov

Other trials for Cardiogenic shock

Additional recruiting or active studies for the same condition.

See all trials for Cardiogenic shock →

← Back to all trials